Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2025	Dec. 31, 2024
Current Assets:
Cash	$ 385,929	$ 307,442
Restricted cash	30,542	182,284
Prepaid expenses and other current assets	151,849	487,046
Total Current Assets	568,320	976,772
Equipment and furnishings, less accumulated depreciation of $119,082 and $118,151, respectively	3,931	4,863
Operating lease right-of-use asset	150,133	24,624
Total Assets	722,384	1,006,259
Current Liabilities:
Accounts payable	1,311,038	1,106,551
Unearned grant revenue		336,108
Other accrued expenses	2,623,420	2,175,376
Notes payable	54,337	206,463
Operating lease liability, current portion	46,232	25,299
Total Current Liabilities	6,493,239	6,975,484
Operating lease liability, non-current portion	103,900
Total Liabilities	6,597,139	6,975,484
Commitments, contingencies, and litigations (Note 13)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized;420,279,879 shares issued and outstanding at June 30, 2025 and December 31, 2024	420,280	420,280
Additional paid-in capital	254,131,964	251,090,027
Accumulated other comprehensive loss	(60,361)	(60,741)
Accumulated deficit	(260,377,489)	(257,422,961)
Total stockholders’ deficit attributable to Provectus Biopharmaceuticals, Inc., stockholders	(5,870,925)	(5,959,332)
Non-controlling interest in subsidiary	(3,830)	(9,893)
Total Stockholders’ Deficit	(5,874,755)	(5,969,225)
Total Liabilities and Stockholders’ Deficit	722,384	1,006,259
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock,value	957	957
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock,value	13,724	13,106
Nonrelated Party [Member]
Current Liabilities:
Accrued interest	26,344	27,774
Convertible notes payable	650,000	853,000
Related Party [Member]
Current Liabilities:
Accrued interest	121,868	144,913
Convertible notes payable	$ 1,660,000	$ 2,100,000